Arbutus Biopharma Corporation
ABUS
$5.16
-$0.02-0.39%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1,078.78% | 2,889.93% | 128.21% | 116.64% | 53.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,078.78% | 2,889.93% | 128.21% | 116.64% | 53.23% |
| Cost of Revenue | -52.58% | -57.13% | -53.29% | -53.74% | -45.35% |
| Gross Profit | 840.91% | 515.25% | 76.69% | 74.24% | 62.26% |
| SG&A Expenses | -10.43% | -29.51% | -28.11% | -24.81% | -22.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -38.71% | -48.23% | -45.98% | -46.11% | -39.51% |
| Operating Income | 463.73% | 343.02% | 61.34% | 60.08% | 50.83% |
| Income Before Tax | 382.12% | 309.90% | 52.09% | 44.88% | 29.62% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 382.12% | 309.90% | 52.09% | 44.88% | 29.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 382.12% | 309.90% | 52.09% | 44.88% | 29.62% |
| EBIT | 463.73% | 343.02% | 61.34% | 60.08% | 50.83% |
| EBITDA | 473.13% | 348.37% | 61.09% | 60.24% | 51.20% |
| EPS Basic | 376.38% | 305.07% | 53.56% | 47.91% | 35.30% |
| Normalized Basic EPS | 519.31% | 368.27% | 65.01% | 64.98% | 57.52% |
| EPS Diluted | 368.63% | 299.83% | 52.93% | 47.53% | 35.09% |
| Normalized Diluted EPS | 515.86% | 366.18% | 65.01% | 64.98% | 57.52% |
| Average Basic Shares Outstanding | 1.89% | 1.59% | 3.24% | 5.89% | 8.74% |
| Average Diluted Shares Outstanding | 1.97% | 1.89% | 3.35% | 6.01% | 8.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |